B+
Bull case
30%
Probability
Target price
$60.00
Analysis reference price unavailable
Analysis 2026-04-22 · RankAlpha Sentiment Codex
CORT
Corcept TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is that March 2026 approval converted ROSELLA from a trial story into a launch story, and the April 2026 full data package strengthened confidence that Lifyorli can become a meaningful ovarian-cancer franchise. Corcept also retains a profitable base business, 2026 revenue guidance of $900-$1,000 million, and $532.4 million of cash, cash equivalents and marketable securities at year-end 2025 [#10-K-2026-02-24] [#IR-2026-02-24].
Posture
Defensive
Lead driver
Value
What changed
3 setup hits (3d) with net bullish as of 2026-10-25.
What can break
Corcept's 2025 net product revenue still came from its existing product base, so oncology-commercial traction must be demonstrated rather than assumed [#10-K-2026-02-24].
Momentum
97
Value
57
Sentiment
9
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $50.00 · Bull $60.00 · Bear $34.00Analysis 2026-04-22; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-22 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Bullish
Target $141.00
Why
Momentum97 · Δ7d -2.5
Value57 · Δ7d -0.0
Sentiment9 · Δ7d +10.1
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-10-25.
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Corcept's 2025 net product revenue still came from its existing product base, so oncology-commercial traction must be demonstrated rather than assumed [#10-K-2026-02-24].
- • Korlym and authorized-generic economics remain exposed to Teva competition and potential future generic entries from Sun or Hikma [#10-K-2026-02-24].
- • The bear case is that Corcept still depends heavily on its Cushing's franchise and faces generic Korlym pressure after Teva's launch and the February 19, 2026 appellate loss disclosed in the 10-K, while the hypercortisolism relacorilant program received a Complete Response Letter on December 31, 2025.
Catalyst clock
2026-05-31
Initial Lifyorli launch and demand capture after FDA approval
Lead driver: Value · See fundamentals
Momentum
97
8% active weight
Current posture
7d trendSoftening
Δ7d
-2.5
Δ21d
+1.3
Value
57
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.6
Sentiment
9
45% active weight
Current posture
7d trendImproving
Δ7d
+10.1
Δ21d
+10.1
Why this grade
Composite grade F. Momentum 96.9 / Value 56.9 / Sentiment 9.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-22. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$50.00
Analysis reference price unavailable
Analysis 2026-04-22 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$34.00
Analysis reference price unavailable
Analysis 2026-04-22 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$9.28B
Beta
0.24
Shares Out
108.1M
P/E (TTM)
39.5
P/S (TTM)
4.96
P/FCF (TTM)
22.54
Rev YoY
+31.7%
EPS YoY
+23.9%
Gross Margin
+98.3%
Op Margin
+0.8%
Net Debt
-$366.05M
Current Ratio
2.83
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data